Free Trial

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.87 0.00 (-0.46%)
As of 07/25/2025 11:50 AM Eastern

BPCR vs. ABDN, ATST, PHLL, 3IN, JGGI, BUR, RCP, BPT, EMG, and MNKS

Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include abrdn (ABDN), Alliance Trust (ATST), Petershill Partners (PHLL), 3i Infrastructure (3IN), JPMorgan Global Growth & Income (JGGI), Burford Capital (BUR), RIT Capital Partners (RCP), Bridgepoint Group (BPT), Man Group (EMG), and Monks (MNKS). These companies are all part of the "asset management" industry.

BioPharma Credit vs. Its Competitors

BioPharma Credit (LON:BPCR) and abrdn (LON:ABDN) are both financial services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

BioPharma Credit has higher revenue and earnings than abrdn. BioPharma Credit is trading at a lower price-to-earnings ratio than abrdn, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£12.99B0.08£10.42B£0.099.89
abrdn£1.49B2.44£316.36M£17.5911.59

abrdn has a consensus target price of GBX 184.33, suggesting a potential downside of 9.55%. Given abrdn's stronger consensus rating and higher possible upside, analysts plainly believe abrdn is more favorable than BioPharma Credit.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioPharma Credit
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
abrdn
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

BioPharma Credit has a net margin of 80.20% compared to abrdn's net margin of 21.19%. BioPharma Credit's return on equity of 8.51% beat abrdn's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit80.20% 8.51% 4.98%
abrdn 21.19%6.46%0.68%

41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 38.2% of abrdn shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by company insiders. Comparatively, 2.4% of abrdn shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, abrdn had 2 more articles in the media than BioPharma Credit. MarketBeat recorded 2 mentions for abrdn and 0 mentions for BioPharma Credit. BioPharma Credit's average media sentiment score of 0.00 equaled abrdn'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
abrdn Neutral

BioPharma Credit has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, abrdn has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 804.6%. abrdn pays an annual dividend of GBX 15 per share and has a dividend yield of 7.4%. BioPharma Credit pays out 7,957.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. abrdn pays out 85.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

abrdn beats BioPharma Credit on 9 of the 17 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

MetricBioPharma CreditAsset Management IndustryFinancial SectorLON Exchange
Market Cap£1.03B£1.31B£6.42B£3.02B
Dividend Yield13.43%4.38%4.18%5.02%
P/E Ratio9.8922.5114.07160.65
Price / Sales0.082,365.201,727.91278,114.27
Price / Cash1.1960.71128.3827.97
Price / Book0.011.231.964.70
Net Income£10.42B£264.35M£1.24B£5.90B
7 Day Performance-1.36%0.05%0.45%0.40%
1 Month Performance-1.14%1.38%2.74%7.19%
1 Year Performance-1.81%6.40%23.55%70.37%

BioPharma Credit Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.87
-0.5%
N/A-1.8%£1.03B£12.99B9.89N/A
ABDN
abrdn
0.6116 of 5 stars
GBX 201.80
+1.6%
GBX 184.33
-8.7%
+21.2%£3.61B£1.49B11.474,719
ATST
Alliance Trust
N/AN/AN/AN/A£3.58B£652.76M600.003
PHLL
Petershill Partners
3.0955 of 5 stars
GBX 238.50
+0.6%
GBX 292.50
+22.6%
+9.4%£3.24B£706.00M9.68N/AAnalyst Forecast
3IN
3i Infrastructure
N/AGBX 345.12
+0.0%
N/A+2.3%£3.18B£374M908.22N/ANews Coverage
Positive News
JGGI
JPMorgan Global Growth & Income
N/AGBX 571.25
+1.1%
N/A+2.1%£2.95B£660.56M4.71N/ANews Coverage
BUR
Burford Capital
2.3624 of 5 stars
GBX 1,042
+0.7%
GBX 1,600
+53.6%
-3.8%£2.87B£299.55M18.64140
RCP
RIT Capital Partners
N/AGBX 1,924.10
+0.7%
N/A+3.2%£2.77B£103.46M16.6362News Coverage
BPT
Bridgepoint Group
1.7691 of 5 stars
GBX 322.42
-0.2%
GBX 371
+15.1%
+21.2%£2.66B£272.35M58.57391News Coverage
Gap Up
EMG
Man Group
1.8901 of 5 stars
GBX 184.30
+0.5%
GBX 235.80
+27.9%
-30.6%£2.66B£1.69B8.691,790
MNKS
Monks
N/AGBX 1,332.79
+0.8%
N/A+16.6%£2.57B£610.03M4.33N/A

Related Companies and Tools


This page (LON:BPCR) was last updated on 7/27/2025 by MarketBeat.com Staff
From Our Partners